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Schistosomiasis japonica, a zoonotic disease caused by the 
Asian schistosome or blood fluke, Schistosoma japonicum, 
is still recognized as a major public health problem in 
China and is, perhaps, the nation’s most important parasitic 
disease. An estimated 1.5 million people are infected, and 
over 40 million people are at risk for the disease in the 
Yangtze River valley provinces.’ Thousands of new cases 
of acute schistosomiasis have been reported in recent years 
from endemic areas. A variety of measures have been 
adopted in an integrated approach to control schistoso- 
miasis japonica in China. These measures rely predomi- 
nantly on mass chemotherapy with the drug praziquantel; 
however, efforts to control schistosomiasis in China with 
extensive use of praziquantel administered to infected 
patients have been thwarted by three major problems. 
First and foremost, high rates of reinfection with schisto- 
somes occur within months following treatment, particu- 
larly in hyperendemic areas. lo Second, there are potential 
and proven concerns about emerging praziquantel drug 
resistance.‘J Third, the reservoir of domestic animal hosts, 
including cattle, buffaloes, pigs, and sheep, represent a sig- 
nificant source for zoonotic transmission of S. japonicum 
to humans; these animal reservoirs are generally not tar- 
geted for mass chemotherapy L* 
As an alternative approach to the control of schisto- 
somiasis japonica, we have genetically engineered schis- 
tosome vaccine antigens that significantly reduce host 
morbidity when used as immunogens. The vaccines are 
potentially suitable for both humans and animal hosts 
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that act as reservoirs. This review deals with the ongoing 
progress in the development of a schistosomiasis japon- 
ica vaccine in China. All studies were done with a Chi- 
nese strain of Xjaponicum, originally collected in 
Oncomelania hupensis hupensis snails from Guichi 
county, Anhui province. 
GOALS FOR VACCINATION 
With the exception of nematode parasites belonging to 
the genera Strongyloides and Capillaria, parasitic 
helminths do not replicate in their mammalian hosts. For 
that reason, the amount of disease caused by parasitic 
helminth infection is usually proportional to the worm 
burden. Therefore, the observation that sterilizing immu- 
nity has never been achieved with an immunogen need 
not discourage us from attempts at developing helminth 
vaccines. Instead, the goals of vaccination are either to 
reduce the worm burden to the point below a threshold 
at which disease could result, or to elicit antidisease 
effects directly by immunization. In the case of acute 
hepatosplenic schistosomiasis, disease occurs when schis- 
tosome eggs are deposited in the liver and intestinal wall 
to cause fibrosis. 
Our major aim is to reduce the morbidity of schis- 
tosomiasis either by reducing the number of schistosome 
worm pairs or by limiting egg deposition in the liver and 
intestine. An antidisease vaccine might also reduce fecal 
egg excretion; in the case of schistosomiasis japonica (but 
probably not in that of S. mansoni or S. haematobium), 
a vaccine could be used to immunize domestic animal 
reservoirs and limit egg excretion, which might other- 
wise result in zoonotic transmission to humans. 
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The initial approach to the development of a schistosome 
vaccine in China relied predominantly on live attenuated 
larval vaccines. Cercariae and schistosomula, attenuated 
with gamma rays, x-rays, or ultraviolet (UV) irradiation, 
have been reported to elicit protective immunity against 
schistosomiasis. Overall, immunization with radiation- 
176 
Vaccine against Schistosomiasis in China / Liu et aE 177 
attenuated cercariae reduces the worm burden between 
33% and 77% in laboratory mice. Vaccination of mice to 
cercariae of Sjaponicum attenuated with 300,400, and 
500 kw/min/cm* resulted in a reduction of the worm 
burden of 49%, 69%, and 60%, respectively (P c: 0.05).3 
Moreover, the reduction of eggs both in the liver 
(57-69%) and intestine (76~80%) tissues was significant 
(P < O.Ol).* There was no correlation between the 
amount of resistance and whether single or multiple 
immunization had been carried out. Protection using UV- 
attenuated cercariae lasted 5 to 7 months and was noted 
to be associated with both humoral immunity and natural 
killer cells recovered from the spleen of immunized 
mice.5 Comparable reductions in worm burden resulted 
when mice were immunized with gamma ray-irradiated 
cercariae of S. japonicum. The maximal protection against 
S. japonicum challenge-infections was obtained by immu- 
nizing mice with 500 cercariae exposed to 24 to 48 krad.6 
Both the number of proliferating T lymphocytes and the 
amount of serum IgG antibody recovered from vacci- 
nated mice were noted to increase 14 days after im- 
munization and peaked on day 28 post-challenge.6x7 
Protection against challenge infections using radia- 
tion-attenuated schistosomes has also been observed in 
domestic pigs, sheep, and buffaloes. These domesticated 
animals represent a significant reservoir of S. japonicum, 
and their vaccination offers an approach to control schis- 
tosomiasis by interrupting its zoonotic transmission. Pigs 
and buffaloes, immunized with three doses each of 10,000 
W-irradiated (400 kw/min/cm2) S. japonicum cercariae 
were protected to 90% against challenge infections of 
1000 untreated cercariae (P < 0.001).8 The challenge cer- 
cariae were administered either 2.5 or 6 months after 
porcine immunization and 90 days after bovine immu- 
nization. Just as in immunized mice, the fecundity of 
female schistosomes was reduced in both immunized 
pigs (over 90% reduction) and buffaloes (86% reduction; 
P < 0.001).*~9 
Bovine intradermal immunizations using either cryo- 
preserved irradiated (Cl) or freeze/thawed (FT) schisto- 
somula in the presence of bacillus Calmette-Gu&in (BCG) 
were also effective in reducing the S. japonicum worm 
burdens compared with BCG controls. A single intrader- 
mal vaccination in buffaloes and cattle with 10,000 CI 
(20 krad) schistosomula provided 62% and 55% worm 
reduction, respectively (P < 0.05).10 Intradermal vaccina- 
tion with 30,000 FT schistosomula with BCG provided 
57% protection (P < 0.05).l” Comparable rates were 
obtained in CI and FT schistosomula-immunized sheep.” 
The intradermal immunizations elicited specific prolifer- 
ative cellular immune responses as early as 4 weeks after 
challenge. The lymphoproliferative responses were tran- 
sient and were significantly diminished at 8 weeks after 
challenge. Responses of IgG antibody developed some- 
what later, at 6 weeks post-challenge, but were found to 
persist for as long as 14 weeks after the challenge.‘O 
In addition to ionizing radiation, the alkylating muta- 
gen N-methyl-N’-nitro-N-nitrosoguanidine (NTG) will also 
attenuate a multicellular organism, but without dimin- 
ishing its immunogenicity.12 In order to prepare the 
immunogen, cercariae are typically attenuated by expos- 
ing them to NTG at a concentration of 30 kg/mL for 
15 minutes. Immunization of NTG-attenuated cercariae 
elicits high levels of protection as measured by reduc- 
tions in the worm burden (77%; P < 0.05), and hepatic 
granulomas.13,‘* Prominent antibody and cellular immune 
responses can be measured after NTG-attenuated cer- 
carial immunizations.15 
Thus, the use of the live cercarial vaccines attenu- 
ated either by ionizing radiation or alkylating mutagens, 
offers an approach to reduce the worm burden and the 
hepatosplenic pathology in laboratory and domestic ani- 
mals. The live vaccines are suitable for inducing protec- 
tion in the laboratory, but they are generally not 
considered a practical means of vaccinating humans or 
domestic animals in the field. The reasons for this include: 
(1) the production costs and labor-intensive efforts 
required to obtain large numbers of cercariae from 
infected Oncomelania snails; (2) the difficulties in stan- 
dardizing the dose of ionizing radiation in order to induce 
cercarial attenuation; (3) the requirement for cryo- 
preservation in order to transport attenuated cercariae 
over long distances; and (4) the potential toxicity of 
administering a live vaccine. To circumvent these prob- 
lems, our group and others in China have attempted to 
reproduce or even improve the protection afforded by 
attenuated cercarial vaccines by substituting chemically 
defined schistosomal antigens genetically engineered in 
bacteria or yeasts. To date, promising results have been 
obtained with three major classes of recombinant mole- 
cules, the enzyme glutathione S-transferase, triosephos- 
phate isomerase, and paramyosin. 
Glutathione S-Transferase (GST) 
Pairs of adult schistosome worms, residing in intestinal 
veins, are exposed to high doses of toxic products when 
organic molecules enter the portal circulation from the 
host gut. Schistosomal GSTs are parasite-derived conju- 
gating enzymes that presumably function to detoxify sev- 
eral classes of organic molecules. Some investigators have 
proposed that GSTs are a major target for praziquantel.‘” 
Each of the two major classes of schistosomal GSTs, the 
26 kDa and the 28 kDa forms, in turn consists of several 
isoforms. Immunization of mice with the 26 kDa form 
(Sj26), which was genetically engineered from a Philip- 
pine strain of S. japonicum, resulted in modest (26 to 
32%) protection upon challenge with a Chinese strain.17-19 
In order to improve on this result efforts were made to 
clone the corresponding cDNA from the Chinese strain. 
By glutathione agarose-affinity chromatography, both 
forms of GST were biochemically isolated from our 
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laboratory strain of Chinese S. japonicum.20 Although a 
modest reduction in worm burden was also obtained by 
immunizing with these native products, we observed a 
striking reduction in the number of eggs excreted by 
female schistosomes recovered from their immunized 
murine hosts.21 In order to follow up on these studies, we 
cloned a cDNA, coding for sj26 from Chinese S. japon- 
icum and expressed and purified the recombinant pro- 
tein.21 Immunization of mice with recombinant Sj26 
(rSj26) with Freund’s adjuvant resulted in a significant 
(71%, P < 0.01) reduction in the number of eggs excreted 
by female schistosomes with a corresponding reduction 
in liver granulomas. The worm burden was reduced by 
29%.‘l 
Therefore, immunization with Chinese rSj26 will elicit 
significant anti-fecundity effects in female schistosomes, 
which mature as a result of the challenge dose. Since 
each schistosome egg has the potential for causing a liver 
granuloma, the antifecundity effect of rSj26 vaccination 
will dramatically reduce the number of granulomas pre- 
sent in the liver. Thus, the disease resulting from acute 
hepatosplenic schistosomiasis can be eliminated by vac- 
cination. To confirm the antidisease vaccine effect of rSj26 
immunization, immunization and challenge experiments 
using rSj26 were undertaken in domestic animal reservoir 
hosts. Immunization with rSj26 using alum as the only 
adjuvant, resulted in a 54% reduction (P < 0.05) in the 
total number of eggs and a 72% reduction in the number 
of mature eggs in the livers of vaccinated pigs (P < 
0.01).22 These trials were subsequently confirmed in 
water buffaloes in which the pronounced antifecundity 
effects resulting from rSj26 immunization caused signifi- 
cant reductions in the number of eggs released into the 
feces and deposited in the liver, spleen, and intestinal 
mucosa and submucosa.23 The hatching capacity of the 
schistosome eggs into viable miracidia was also 
impaired. 23 In order to improve the Chinese rSj26 vac- 
cine, the cDNA was cloned and expressed in bacille Cal- 
mette-Guerin (BCG). For these studies, the cDNA was 
placed under the control of a Mycobacterium tubercu- 
losis heat-shock protein-70-promoter prior to ligation into 
an Escherichia coli / mycobacterium shuttle plasmid 
(pBCG-2000).‘* The expressed rSj26 was found to rep- 
resent approximately 18% of the total cellular protein. 
Large-scale field trials under natural conditions, using both 
purified rSj26 (expressed in E,coZi) and BCG (expressing 
Sj26), are now underway in Hunan Province. These trials 
determine whether immunization of water buffaloes with 
these vaccines will reduce the excretion of eggs and the 
hepatosplenic schistosomiasis when the animals are 
allowed to graze in a hyperendemic area. 
Paramyosin 
Paramyosin is a major structural protein of thick filaments 
in invertebrate muscle. The absence of a homologous 
protein in vertebrates makes paramyosin a potentially 
useful candidate for a vaccine. The native 97kDa 
paramyosin was isolated from both adult Chinese schis- 
tosomes and its snail vector, Oncomelania hupensis 
hupensis using previously published methods,25,26 and 
used as an immunogen in mice. Mice vaccinated with 
20 pg of native paramyosin and Freund’s adjuvant showed 
reductions in worm burden and egg excretion compared 
with adjuvant alone. Immunization with schistosomal 
paramyosin resulted in a 26% reduction in worm burden 
(P < 0.01) and a 40% reduction in egg excretion (P < 
0.05), whereas immunization with snail paramyosin 
caused a reduction of 34% in worm burden (P < 0.01) 
and a 20% reduction in egg excretion, respectively.ls Sim- 
ilar immunizations using BCG gave even less promising 
results.25 
Sj31 
A 31 kDa antigen of unknown function was isolated from 
adult Chinese schistosomes by ACA-54-super-gel chro- 
matography and preparative gel electrophoresis.28 
Although immunization of mice with Sj3 1 did not reduce 
the worm burden upon challenge, it did result in a sig- 
nificant reduction, compared to controls, in fecal egg 
excretion (63-78%, P < 0.01) eggs in the liver (44%, P < 
0.01) eggs in the intestinal wall (48%, P < 0.01) and eggs 
in the uteri of female schistosomes (53%, P < 0.01). In 
another laboratory S. japonicum 3 l/32 kDa proteins were 
also isolated on polyacrylamide slab gels and purified by 
elution from electrophoresis gels. Immunization with 
these proteins reduce the worm burden (28%; P < 0.001) 
the fecundity of female worms (71%; P < 0.001) and the 
size of egg granulomas in mouse livers (37-70%; P < 
0.001).29 Immunization resulted in a substantial increase 
in the number of nonviable eggs in the intestine and liver 
of immunized mice (59% and 66%) (p < 0.01).28 
Triosephosphate Isomerase 
Triosephosphate isomerase (TPI) isolated from adult Chi- 
nese S. japonicum by acetone precipitation and heat 
treatment,16 was evaluated as a vaccine antigen in mice. 
Immunization of mice with TPI and Freund’s adjuvant 
resulted in a significant reduction (58-60% P < 0.01) in 
liver granulations. Some reduction in worm burden 
(21-25%, P < 0.05) was also obtained.30 The TPI cDNA 
was obtained by a reverse-transcriptase polymerase-chain- 
reaction (RTPCR) using total S. japonicum RNA as tem- 
plate and primers designed according to the published 
cDNA sequencing of S. mansoni TPI.” Expression of the 
TPI-cDNA of S. japonicum and evaluation of the vaccine 
potential for rTP1 are in progress. 
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FUTURE STUDIES 
The immunologic mechanisms leading to suppression of 
egg production and hatching induced by rsj26 and Sj31 
remain to be elucidated. In addition, the duration of the 
observed antifecundity effects afforded by vaccination 
are not yet known. Studies are also underway to evaluate 
whether a “cocktail” of more than one antigen might 
improve existing subunit vaccines. Alternatively, immu- 
nizing with naked DNA coding for these antigens might 
obviate the need to isolate recombinant proteins or even 
improve protection by eliciting strong Thl immune 
responses. Because DNA vaccines are more heat-stable 
than recombinant proteins, they are particularly attrac- 
tive for use in the tropical and subtropical climates of 
Cbina’sYangtze River valley provinces. Studies using GST 
and TPI DNA vaccines are in progress. 
The genetic diversity of genes that code for vaccine 
antigens will also be investigated. For instance, although 
there is a high degree of predicted amino acid homol- 
ogy between the Sj26 genes of Chinese and Philippine 
strains of S. japonicum, there are substantial differences 
between the TPI genes of the two strains. The authors are 
currently investigating whether variations in cDNA and 
predicted amino acid sequences among different provin- 
cial strains are also sufficiently great to warrant produc- 
ing designer-vaccines for each of the majoryangtze River 
valley provinces. For example, the rSj26 vaccine used in 
Anhui Province might one day differ from the one used 
in Sichuan Province. 
Over the next few years we expect to obtain data 
on the efficacy of both rSj26 and rTP1 vaccines currently 
being tested in water buffaloes under natural field con- 
ditions. Encouraging results in these studies will prompt 
investigations to determine whether veterinary use of 
the vaccines is sufficient to interrupt the transmission of 
schistosomiasis japonica to humans, or whether human 
vaccination will be required. 
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